This photo provided by ALS patient Brian Wallach shows him and his wife, Sandra Abrevaya, at their home in Chicago on May 2021. Wallach, who formed I AM ALS with Abrevaya after being diagnosed with ALS in 2017, spent years working on legislation with congressional staffers, researchers and patients which passed the House last December in a landslide 423-3 vote.
Only patients who can't get into conventional drug trials are eligible for the program. And their progress must be tracked to gather data about the treatment and their underlying disease, amyotrophic lateral sclerosis, or ALS. Up to 90% of ALS patients are ineligible for traditional clinical trials, according to researchers, typically because their disease has progressed too far to show major treatment benefits. Even eligible patients must compete for access. One recent analysis counted 2,000 trial openings in the U.S. for 25,000 people living with ALS.
The NIH spends the vast majority of its $45 billion budget on early-stage research focused on identifying the root causes, treatments and potential cures for diseases. “I’m five years in so I can’t qualify for any clinical trials,” said Brian Wallach, who launched I AM ALS with his wife after being diagnosed in 2017. “I hope to be eligible for the expanded access pathway.”
The legislation grew out of patients' deep frustration with access to experimental therapies, including a stem cell treatment from the tiny drugmaker Brainstorm Cell Therapeutics.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WOKVNews - 🏆 247. / 63 Read more »
Source: NBCDFW - 🏆 288. / 63 Read more »